Comparative Pharmacology
Head-to-head clinical analysis: TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus U GENCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER versus U GENCIN.
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs U-GENCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting protein synthesis in susceptible bacteria.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
3-5 mg/kg/day IV divided every 8 hours or 5-7 mg/kg IV once daily for adults with normal renal function.
1-2 mg/kg IV every 8 hours for 7-10 days, targeting peak serum concentration of 6-10 mcg/mL and trough <2 mcg/mL.
None Documented
None Documented
2-3 hours in patients with normal renal function; prolonged to 24-60 hours in anuria. Half-life is directly correlated with creatinine clearance.
Terminal elimination half-life is 2-3 hours in patients with normal renal function; may prolong to 20-40 hours in end-stage renal disease
Primarily renal (glomerular filtration) with >90% excreted unchanged in urine within 24 hours; minimal biliary/fecal (<1%).
Primarily renal (glomerular filtration) with 40-70% excreted unchanged in urine within 24 hours; minor biliary/fecal (<5%)
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic